First author [ref. no.] | Design | Patients active treatment/patients | RSV positive % | Age at enrolment, mean/median months | Treatment | Follow-up time | Result at time of follow-up |
Studies not demonstrating no effect at time of follow-up | |||||||
Blow 21 | RCT | 73/74 | 100 | 5.5 | Oral prednisolone for 5 days | 1 yr | No effect of the treatment |
van Woensel 102 | RCT | 24/23 | 100 | 3.6 | Oral prednisolone acutely for 7 days | 5 yrs | No significant difference in transient, persistent or late-onest wheezing, 8% versus 17%, 42% versus 31% and 17% versus 13%# |
Cade 24 | RCT | 82/79 | 100 | 4 | Nebulized budesonide until 2 weeks after discharge | 1 yr | No long-term benefits of the active teatment |
Richter 20 | RCT | 21/19 | 83 | 3.5 | Nebulized budesonide for 6 weeks | 6 months | No prevention of postbronchiolitic wheezing |
Fox 103 | RCT | 25/24 | 65 | 2.5 | Inhaled budesonide for 8 weeks | 1 yr | Treated infants did not have less postbronchiolitic wheezing |
Reijonen 104 | RCT | 31/28 | 26 | 10.6 | Nebulized budesonide for 4 months | 1 yr | The treatment did not significantly decrease occurrence of asthma 1 yr later |
Reijonen 105 | RCT | 31/29 | 26 | 10.6 | Nebulized budesonide for 4 months | 3 yr | Nebulized corticosteroids for 4 months had no influence on the occurrence of asthma 3 yrs later |
Studies demonstrating positive effect at time of follow-up | |||||||
Kajosaari 106 | RCT | 71/38 | 100 | 2.6 | Nebulized budesonide for 7 days or 2 months | 2 yrs | Fewer treated children on continuous asthma medication |
Carlsen 107 | RCT | 22/22 | No percentage given | 15.7 | Nebulized BDP for 8 weeks | 14 weeks | Fewer obstructive symptoms during the follow-up period |
Reijonen 89 | RCT | 31/30 | 26 | 10.6 | Nebulized budesonide for 4 months | Weeks 9–16 | Treated children had fewer wheezing episodes and hospital admissions. Particularly children with atopy benefited. |
RCT: randomized controlled trial
BDP: beclomethasone diproprionate
#: active versus placebo